Transperineal template prostate-mapping biopsies: an evaluation of different protocols in the detection of clinically significant prostate cancer by Valerio, M et al.
ABSTRACT 
 
Objectives 
To determine whether modified transperineal template prostate mapping (TTPM) biopsy 
protocols, altering the template or the biopsy density, have sensitivity and negative predictive 
value equal to full 5mm TTPM. 
 
Materials and Methods 
Retrospective analysis of an institutional registry including treatment-naïve men undergoing 
5mm TTPM analysed in 20 zones fashion. The value of three modified strategies was 
assessed by comparing the information provided by selected zones against full 5mm TTPM. 
Strategy 1 did not consider the findings of anterior areas; strategies 2 and 3 simulated a 
reduced biopsy density by excluding intervening zones. A bootstrapping technique was 
employed to calculate reliable estimates of sensitivity and negative predictive value of these 
three strategies with respect to detection of clinically significant disease (maximum cancer 
core length >/= 4mm and/or Gleason score >/= 3+4). 
 
Results 
391 men with median age 62 years (IQR 58-67) were included. Median PSA and PSA 
density were 6.9 ng/ml (IQR 4.8-10) and 0.17 (IQR 0.12-0.25), respectively. A median of 6 
cores (IQR 2-9) out of 48 taken per man (IQR 33-63) were positive for prostate cancer. No 
cancer was detected in 67 men (17%), whilst low, intermediate and high risk disease was 
identified in 78 (20%), 80 (21%) and 166 (42%), respectively. Strategy 1, 2 and 3 had 
sensitivities of 78% (95% CI 73-84%), 85% (95% CI 80-90%) and 84% (95% CI 79-89%), 
respectively. The negative predictive values of the three strategies was at 73% (95% CI 67-
80%), 80% (95% CI 74-86%) and 79% (95% CI 72-84%), respectively. 
 
 
Conclusion 
Altering the template or decreasing sampling density has a substantial negative impact on 
the ability of TTPM to rule out clinically significant disease. This should be considered when 
modified TTPM strategies are performed to select men for tissue-preserving approaches, 
and when modified TTPM are employed to validate new diagnostic tests. 
  
Introduction 
 
The management of localised prostate cancer has been fraught with errors in attributing 
cancer risk due to the inaccuracies of the transrectal ultrasound guided (TRUS) biopsy [1]. A 
number of studies have shown that in around half of men undergoing radical prostatectomy, 
the prediction of grade and/or stage is wrong [2-4]. The true degree of diagnostic error is 
difficult to ascertain as those men with a negative TRUS biopsy do not usually undergo a 
more accurate verification test. 
 
There have been attempts to increase the diagnostic value of sampling techniques other 
than the standard 10-12 core TRUS biopsy. Increasing the sampling density of transrectal 
biopsy using pre-established templates – so-called saturation biopsy – have met with 
variable results [5, 6]. For instance, despite initial encouraging results, a recent large multi-
centre randomized controlled trial has shown that there was no increased detection of 
disease using this approach compared to a standard one [7]. 
 
Yet others have proposed that the sampling strategy should switch to incorporate a 
transperineal route as this allows a more systematic approach to the whole prostate including 
apex and anterior regions which are often missed on TRUS biopsy. However, transperineal 
biopsies can be performed in a number of different ways with varying biopsy densities. These 
can generally be categorised into those that first, map the prostate by taking biopsies every 
5mm [8-11] or second, those that sample regions of the prostate but with reduced density of 
cores [12-15]. Whilst computer simulation studies demonstrate less sensitivity in detecting 
lesions that are >0.5cc or >0.2cc in volume when using a 10mm sampling frame compared to 
taking biopsies every 5mm [16], it is not known whether this is the case in patients. The aim 
of our study was to test whether diagnostic accuracy vary, and if so to what extent, when 
using different transperineal biopsy strategies.  
 
Materials and Methods 
 
Ethics committee exemption was granted for our study which involved evaluating our 
template transperineal prostate mapping (TTPM) biopsy institutional registry. The TTPM 
biopsy registry includes all patients undergoing this procedure from 05/2006 till the 01/2012. 
Men having TTPM biopsy after local or systemic prostate cancer treatment were excluded; 5-
alpha reductase inhibitors were permitted. 
 
TTPM biopsies were performed following a modified-Barzell template with a 5mm density as 
previously reported [11]. The procedure was carried out under general anaesthesia with 
single dose intravenous antibiotics. After positioning a urethral catheter, the urethra was 
aligned in the ‘D3’ or ‘D2.5’ grid position at the largest axial part of the prostate, and using a 
5mm frame, at each coordinate one to two cores were taken in order to sample the whole 
prostate in the cranio-caudal axis. The prostate was divided in 20 zones and each core taken 
was potted and analysed within the respective area (figure 1). Histopathology results were 
given per zone, and included number of total cores taken, number of positive cores, Gleason 
score, maximum cancer core length and total cancer length.  
 
For the purpose of the study, clinically significant disease was defined using the UCL risk 
classification, previously developed for TTPM biopsy findings (figure 1) [11]. We considered 
the sum of UCL intermediate- (Gleason >/=3+4 and/or maximum cancer core length 
>/=4mm) and high-risk disease (Gleason >/=4+3 and/or maximum cancer core length 
>/=6mm) as clinically significant.  
 
The detailed manner in which the TTPM biopsy data was collected, with a high spatial 
resolution of risk attribution, permitted us to determine the impact of changing our template 
transperineal biopsy strategies. In effect, we excluded certain zones from contributing 
diagnostic information to the overall risk attribution to evaluate the effect of removing these 
zones. We evaluated three strategies in total. Strategy 1 involved excluding the anterior 
areas of the prostate representing the transition area, but not the anterior horns which were 
sampled within the lateral zones. Strategy 2 and strategy 3 involved a reduced sampling 
density from 5mm to 10mm by taking out intervening areas. The difference between these 
latter two strategies was related to which zones were excluded from contributing diagnostic 
information, as shown in figure 2. These three strategies were then compared to what we 
deemed the reference standard, the full 5mm TTPM biopsy result. 
 
Statistics 
Standard evaluation of diagnostic tests includes the determination of four parameters: 
sensitivity, specificity, positive predictive value and negative predictive value. In this case, 
since the index tests (the three sampling strategies) were not independent of the reference 
test (5mm TTPM) the calculation might have wrongly led to over-estimation of specificity and 
positive predictive value; therefore, we determined only sensitivity and negative predictive 
value with respect to clinically significant disease. To calculate reliable estimates, a 
bootstrapping technique was employed to mimic the sampling distribution. We used 500 
repeat simulations for each dataset to estimate proportions and calculate 95% confidence 
intervals (CI). The statistical analysis was performed using the STATA® software version 
11.1 (Stata Corp. 2009, Stata Statistical Software: Release 11, College Station, TX, USA). 
 
 
 
Results 
 
Of 485 cases present in the TTPM biopsy registry, 94 were excluded (89 had previous 
treatment; five had incomplete data), leaving 391 evaluable cases for this study. Median age 
was 62 years (IQR 58-67). Median PSA, PSA density and prostate volume were 6.9 ng/ml 
(IQR 4.8-10.0), 0.17 (0.12-0.25) and 39.5 ml (30-52) respectively. 
Most of these patients (69%; 269/391) underwent TTPM biopsy in order to be considered for 
tissue-preserving approaches after an initial diagnosis of prostate cancer based on TRUS 
biopsy, but some of them had previous negative biopsy (19%; 75/391) and a minority had 
TTPM biopsy as the first-line sampling technique (12%; 75/391) (table 1). When a cancer 
diagnosis was already given by prior TRUS biopsy (n=269), the majority were D‘Amico low or 
intermediate risk (Table 1).  
TTPM biopsy results are displayed in table 2. No cancer was found in 17% (67/391); of 
these, 22% (15/67) and 10% (7/67) had a previous diagnosis of low and intermediate risk 
disease, respectively. and 20% (78/391) were considered to harbour low-risk disease by 
UCL criteria (Gleason </=3+3 and cancer core length </=3mm). Clinically significant disease 
was present in 63% (246/391) with 21% (80/391) and 42% (166/391) harbouring 
intermediate- and high-risk disease, respectively. For each Barzell-modified zone, we 
calculated the percentage of men harbouring no cancer, UCL low risk, intermediate and high 
risk prostate cancer. Figure 3 shows risk stratification in a per zone fashion.  
With respect to diagnosis of clinically significant disease, strategy 1, 2 and 3 had sensitivities 
of 78% (95% CI 73-84%), 85% (95% CI 80-90%) and 84% (95% CI 79-89%), respectively 
(table 3). The negative predictive values were lower at 73% (95% CI 67-80%), 80% (95% CI 
74-86%) and 79% (95% CI 72-84%), respectively. 
 
 
 
Discussion 
Our study shows that altering the template transperineal sampling strategy by preferential 
sampling of certain locations or reducing the sampling density leads to significant reductions 
in the ability of the test to rule-out clinically significant prostate cancer when compared to full 
5mm mapping biopsies.  
 
Limitations 
Prior to considering the clinical implications of our study, we would like to acknowledge its 
limitations. First, the study population was heterogeneous. This population reflects the 
practice in our tertiary referral hospital, but might not represent the same population 
undergoing template transperineal biopsies in other centres. Second, the alternative template 
biopsy strategies were artificially simulated and may not fully represent true clinical practice. 
However, we believe our design is an efficient one that allows the derivation of important 
information on clinical validity and utility without having to resort to a randomised design. 
Third, it may be argued that TTPM biopsies using a 5mm sampling density cannot be 
considered a reference test at the same level as radical prostatectomy. While we agree that 
TTPM has a diagnostic inaccuracy of approximately 5%, it should be noted that it can be 
applied to all men, including those with no previous biopsy or negative TRUS findings, or 
those considering treatment options (active surveillance, focal therapy, radiation therapy) 
other than radical prostatectomy. As a consequence, it overcomes the considerable selection 
bias that is inherent in comparing new diagnostic tests that are inherent to whole-mount 
prostatectomy sections. Further, TTPM biopsies have recently been shown to be highly 
accurate in ruling-in and ruling-out clinically significant disease in clinical series in which 
TTPM biopsies were followed by radical prostatectomy [4, 8]. 
 
Clinical implications 
In our study, we sought to evaluate a number of other template transperineal biopsy 
strategies in terms of diagnostic accuracy. There have been various differing reports and 
recommendations for how transperineal biopsies are or should be conducted. One group 
proposed the use of a protocol that included 22 cores from 12 biopsy locations. In a cohort of 
414 men undergoing transperineal biopsy using this strategy, Gleason score upgrading 
occurred in about 25.6% when the results of biopsy were compared to radical prostatectomy 
specimen [15]. Although the template covered the whole prostate, the sampling density was 
likely to be set around 10mm as the median number of cores was 22 and the mean prostate 
volume was around 50cc. In addition, this study clearly showed that the biopsy density 
matters, as the agreement between biopsy and whole-mount histology results was 
significantly lower in the larger prostate, in which the biopsy density was lower. Other groups 
use protocols that preferentially sample the peripheral area while performing limited sampling 
of the anterior part of the prostate [12, 13]. In our study, avoiding the sampling of the 
transition zone led to a decrease in sensitivity and negative predictive value for clinically 
significant disease of over 20%. This means that in at least one man out of five who has a 
negative template biopsy, such as the one we describe in strategy 1, clinically significant 
disease would be missed. This may have important consequences as transperineal biopsy 
are usually offered to men seeking correct risk stratification, and inaccurate results may lead 
to incorrect management.  
 
Recently, experts in the field of prostate diagnosis attempted to define a standardized 
approach to perform transperineal template biopsy in the setting of a consensus meeting 
using validated methodology (UCLA-RAND) [14]. The panellists suggested a variable 
number of cores ranging from 24 to 38, according to prostate volume. Although the outcomes 
of this protocol were not compared to a reference test, we believe that these suggestions 
should be questioned based on our findings. Indeed, this consensus recommendation leads 
to fluctuating biopsy density with low- and mid-volume prostates being sampled with around 
5mm density, and large-volume prostates being less intensively sampled. As a result, in the 
latter group of men, there might be significantly decreased detection rates compared to a 
5mm sampling frame. 
 
 
The use of TTPM biopsies has some problems. It requires general anaesthesia both 
because of pain issues and because patient movements would affect the template precision. 
This means that the systematic use of TTPM has cost and resource implications. Reducing 
the biopsy density might have a positive impact on this, and indeed a recent series has 
shown the feasibility of performing an alternative TTPM strategy under local anaesthesia 
[17]. However, in light of our findings, the reduced cost should be balanced against the 
reduced diagnostic performance and its clinical implications. 
In addition, the high biopsy density of TTPM can lead to hematuria (50%), erectile 
dysfunction (26%) and acute urinary retention (3%), although the morbidity is temporary [18]. 
This has to be weighed against another important advantage of the transperineal approach 
which is the negligible risk (<0.5%) of sepsis compared to the transrectal route (2-4%) [19]. It 
is not clear in the literature, and this is a question we were clearly unable to answer, as to 
whether decreasing the biopsy density or avoiding sampling certain zones might reduce the 
complication rates.  
 
We fully acknowledge that the future strategy might involve the use of targeted biopsy 
directed to MRI suspicious areas of the prostate. This imaging-guided strategy would aim to 
maximise the efficiency and diagnostic accuracy of limited sampling and relies on what 
seems to be a high negative predictive value of a well conducted expertly read multi-
parametric MRI [20]. Some studies have shown similar detection rates of targeted biopsy 
against template mapping biopsy [21, 22]; however, none of these studies compared 
targeted biopsy to systematic 5mm sampling.  
 
As well as being used for accurate risk stratification of disease, template transperineal 
biopsies have also been proposed as the reference test to validate novel imaging tests such 
as multi-parametric MRI (mpMRI). One recent study by Thompson JE et al. attempted to 
determine the accuracy of mpMRI to detect clinically significant prostate cancer using 
transperineal 30-core template biopsy and targeted biopsy as the reference test. mpMRI 
provided excellent (>90%) sensitivity and negative predictive value, whereas the 
performance in terms of specificity and positive predictive value was moderate (~50%) [23]. 
Based on our own findings, the accuracy of mpMRI may actually be over-estimated as the 
reference test in the report by Thompson JE et al. might not be reliable in all men, especially 
in those with large volume glands as it is very similar to strategies 2 and 3. Two ongoing 
multicentre UK trials are assessing the diagnostic value of mpMRI in biopsy-naïve men 
(PROMIS) [24] and in men with prior TRUS biopsy (PICTURE) [25] against 5mm TTPM. This 
design aims to overcome the inaccuracy linked to misclassification and to selection bias 
when using TRUS biopsy or radical prostatectomy specimens, respectively. 
In conclusion, transperineal template biopsies that use reduced sampling densities seem to 
reduce diagnostic accuracy compared to a full template transperineal mapping strategy in 
which biopsies are taken every 5mm. If systematic sampling of the whole prostate is to be 
used using a transperineal approach, men and their physicians should aware of the impact of 
different strategies has on the ability of the test to rule-out clinically significant disease both 
on an individual level but also for the purpose of validating novel imaging tests. 
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Legends 
 
Table 1 
Patients’ characteristics. 
 
Table 2 
Overall 5mm transperineal template prostate mapping biopsies findings. 
 
Table 3 
Sensitivity and negative predictive value of the three TTPM strategies with respect to 
identification of clinically significant prostate cancer. 
 
Figure 1 
Modified Barzell-template biopsy report. Briefly, for readers unfamiliar with this template, 
zones 1-4 and 7-10 include the anterior prostate, 11-12 include the lateral horns, 5-6 and 13-
20 include the posterior prostate. 
 
Figure 2 
Visual representation of the three strategies simulating reported variations of 5mm TTPM.  
 
Figure 3 
Risk stratification in a per zone fashion.  
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